The global therapeutic vaccine market is anticipated to grow at a significant CAGR during the forecast period. The therapeutic vaccine is gaining traction as a favorable solution to the people diagnosed with various infectious as well as non-infectious diseases. The therapeutic vaccine is not a complete cure for diseases, however, it significantly improves the condition and, in some cases, prevents it for recurring. Additionally, therapeutic vaccine application in the R&D related to a fatal disease such as HIV and cancer is rising rapidly, which is anticipated to drive the global therapeutic vaccine market. 

Moreover, factors such as increasing chronic disease, favorable initiatives from governmental and humanitarian organizations, and the minimal side effect are anticipated to trigger the growth of the therapeutic market. However, the limited availability of a therapeutic vaccine is anticipated to hinder the therapeutic vaccine market. Additionally, the reimbursement policies and strict regulation across the countries regarding the development of vaccines will also restrict the growth of the therapeutic vaccine market during the forecast period.

Segmental Outlook 

The therapeutic vaccine market is segmented on the basis of the product and technology. Based on the product, the market is sub-segmented into autoimmune disease vaccines, neurological disease vaccines, cancer vaccines, infectious disease vaccines, and others. Further, based on the technology, the market is bifurcated into the allogeneic vaccine and autologous vaccine.

Global Therapeutic vaccine Market Share by Product, 2019 (%)

Cancer Vaccine will be the Fastest Growing Segment by Product

The cancer vaccine segment is anticipated to show significant growth in the therapeutic vaccine market owing to increasing cases of cancer across the globe. According to Cancer Research UK, in 2018, there were around 17 million new cases of cancer. Additionally, increasing R&D in the field of cancer treatment will also drive the cancer vaccine segment of the therapeutic vaccine market. Moreover, the rising trend of personalized cancer vaccines is also anticipated to impact the cancer vaccine as well as the therapeutic vaccine market during the forecast period.

Regional Outlooks

The global therapeutic vaccine market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in the therapeutic vaccine during the forecast period owing to the well-developed healthcare structure in the region coupled with potentially good awareness regarding the therapeutic vaccine advantages in the region. Additionally, the increased focus of key players of the region on the invention and development of new therapeutic vaccines will also drive the therapeutic vaccine market across the region during the forecast period.

Global Therapeutic Vaccine Market Growth by Region 2020-2026

Asia-Pacific will Augment with the Fastest Growth Rate in the Therapeutic Vaccine Market

Asia-Pacific is anticipated to exhibit the fastest growth rate in the therapeutic vaccine market owing to the increased R&D activities fuelled by the presence of key industry players. Additionally, the technological advancements in the healthcare sector will also drive the growth of the therapeutics vaccine market across the region. Moreover, the rising prevalence of infectious diseases across the region will also impact the growth of the therapeutics market. For instance, the recent outbreak of the COVID-19 virus in December 2020 is raising the requirement of therapeutic vaccines across the region as well as across the globe.

Market Players Outlook

some of the key players of the therapeutic vaccine market include Agenus Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Eli Lilly and Co., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and new drug approvals to stay competitive in the market. 

Recent Activities

• In April 2020, Sanofi SA announced the FDA approval of Meningococcal Conjugate Vaccine called MenQuadfi . It is intended to use for the prevention of invasive meningococcal disease in patients that are older than 2 years.
• In January 2020, Eli Lilly And Co. in collaboration with Innovent Biologics announced the acceptance of sNDA for Tyvyt sintilimab injection by the National Medical Products Administration of China. It has accepted to provide in combination with Alimta and platinum as first-line therapy in non-squamous non-small cell lung cancer. 

The Report Covers

• value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global therapeutic vaccine market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.